CA
CRDF icon

Clearstead Advisors’s Cardiff Oncology CRDF Stock Holding History

Clearstead Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$910 Hold
700
– – ﹤0.01% 2728
2026
Q1 		$1.13K Hold
700
– – ﹤0.01% 2020
2025
Q4 		$1.97K Hold
700
– – ﹤0.01% 2148
2025
Q3 		$1.44K Hold
700
– – ﹤0.01% 2549
2025
Q2 		$2.21K Hold
700
– – ﹤0.01% 2303
2025
Q1 		$2.2K Hold
700
– – ﹤0.01% 1885
2024
Q4 		$3.04K Hold
700
– – ﹤0.01% 1795
2024
Q3 		$1.87K Hold
700
– – ﹤0.01% 1849
2024
Q2 		$1.55K Buy
+700
New +$2.64K ﹤0.01% 1846

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Clearstead Advisors's CRDF Position: Q2 2026 in Review

Clearstead Advisors held its Cardiff Oncology (CRDF) position steady in Q2 2026 at 700 shares worth $910. The position accounts for ﹤0.01% of the portfolio, ranked #2728.

Clearstead Advisors first reported a position in CRDF in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.04K in Q4 2024. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Clearstead Advisors held 700 shares of Cardiff Oncology worth $910 as of Q2 2026.
  • Clearstead Advisors left its Cardiff Oncology share count unchanged in Q2 2026.
  • Cardiff Oncology made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2728 holding.
  • Clearstead Advisors first reported a position in Cardiff Oncology in Q2 2024 and has held it in 9 quarters since.
  • Clearstead Advisors's Cardiff Oncology position peaked at $3.04K in Q4 2024.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.